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2In 2014, an estimated  
6,400 Iowans will die  
from cancer, 16 times the number caused 
by auto fatalities. Cancer and heart disease 
are the leading causes of death in Iowa.  
These projections are based upon mortality 
data the State Health Registry of Iowa 
receives from the Iowa Department of Public 
Health. The Registry has been recording  
the occurrence of cancer in Iowa since 1973, 
and is one of fourteen population-based 
registries and three supplementary registries 
nationwide providing data to the National 
Cancer Institute. With 2014 Cancer in Iowa,  
the Registry makes a general report to  
the public on the status of cancer.  
This report will focus on:
•	 a	description	of	the	Registry		
	 and	its	goals;
•	 cancer	estimates	for	2014;
•	 a	special	section	on	human		
	 papillomavirus	(HPV);
•	 brief	summaries	of	recent/ongoing		
	 research	projects;
•	 a	selected	list	of	publications		
	 from	2013.
3The State 
Health 
Registry 
of Iowa 
Cancer is a reportable disease as stated in the Iowa Administrative Code. Cancer data are collected by the State Health Registry of Iowa, located at 
The University of Iowa in the College of Public Health’s 
Department of Epidemiology. The staff  includes more 
than 50 people. Half of them, situated throughout 
the state, regularly visit hospitals, clinics, and medical 
laboratories in Iowa and neighboring states to collect 
cancer data. A follow-up program tracks more than 99 
percent of the cancer survivors diagnosed since 1973. 
This program provides regular updates for follow-up 
and survival. The Registry maintains the confi dentiality 
of the patients, physicians, and hospitals providing data.
In 2014 data will be collected on an estimated 17,400 
new cancers among Iowa residents. In situ cases of bladder 
cancer are included in the estimates for bladder cancer, 
to be in agreement with the defi nition of reportable 
cases of the Surveillance, Epidemiology, and End Results 
(SEER) Program of the National Cancer Institute. 
Since 1973 the Iowa Registry has been funded by the 
SEER Program of the National Cancer Institute. Iowa 
represents rural and Midwestern populations and provides 
data included in many NCI publications. Beginning in 1990 
about 5-10 percent of the Registry’s annual operating 
budget has been provided by the state of Iowa. Beginning 
in 2003, the University of Iowa has also been providing 
cost-sharing funds. The Registry also receives funding 
through grants and contracts with university, state, and 
national researchers investigating cancer-related topics.
The goals of the Registry are to:
•  assemble and report measurements of cancer   
 incidence, survival and mortality among Iowans;
•  provide information on changes over time in 
 the extent of disease at diagnosis, therapy, and 
 patient survival;
•  promote and conduct studies designed to 
 identify factors relating to cancer etiology,   
 prevention and control; 
•  respond to requests from individuals and    
 organizations in the state of Iowa for cancer 
 data and analyses; 
•  provide data and expertise for cancer research   
 activities and educational opportunities. 
The State Health 
Registry of Iowa is the 
best statewide resource 
for determining the 
burden of cancer on 
the Iowa population 
and assessing trends 
in the occurrence of 
cancer over time.  
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Cancer Projections for 2014
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Projected Number of Cancer Deaths in Iowa for 2014
Projected Number of New Cancers in Iowa for 2014
4
NEW CANCERS IN FEMALES
TYPE	 #	OF	CANCERS	 %	OF	TOTAL
Breast 2350 28.0
Lung 1000 11.9
Colon & Rectum 780 9.3
Uterus 580 6.9
Skin Melanoma 380 4.5
Non-Hodgkin Lymphoma 370 4.4
Thyroid 300 3.6
Leukemia 240 2.9
Kidney & Renal Pelvis 230 2.7 
Ovary 230 2.7
All Others 1940 23.1
TOTAL 8400
NEW CANCERS IN MALES
TYPE	 #	OF	CANCERS	 %	OF	TOTAL
Prostate 2200 24.4 
Lung 1290 14.3 
Colon & Rectum 860 9.6
Bladder  630 7.0
(invasive and noninvasive) 
Skin Melanoma 460 5.1
Non-Hodgkin Lymphoma 420 4.7
Kidney & Renal Pelvis 390 4.3
Leukemia 330 3.7
Oral Cavity 300 3.3
Pancreas 230 2.6
All Others 1890 21.0
TOTAL 9000
CANCER DEATHS IN FEMALES
TYPE	 #	OF	CANCERS	 %	OF	TOTAL
Lung 740 24.7
Breast 400 13.3
Colon & Rectum 290 9.7
Pancreas 210 7.0
Ovary 170 5.7
Non-Hodgkin Lymphoma 120 4.0
Leukemia 120 4.0
Uterus 110 3.7
Brain 70 2.3
Kidney & Renal Pelvis 70 2.3
All Others 700 23.3
TOTAL 3000
CANCER DEATHS IN MALES
TYPE	 #	OF	CANCERS	 %	OF	TOTAL
Lung 950 28.0 
Prostate 330 9.7
Colon & Rectum 300 8.8
Pancreas 210 6.2
Leukemia 160 4.7
Esophagus 150 4.4
Non-Hodgkin Lymphoma 140 4.1
Bladder 120 3.5
Kidney & Renal Pelvis 120 3.5
Brain 100 3.0
All Others 820 24.1
TOTAL 3400
Fortunately for Iowans, the chances of being diagnosed with many types of cancer can be reduced through positive 
health practices such as smoking cessation, physical exercise, healthful dietary habits, and alcohol consumption in 
moderation.  Early detection through self-examination and regular health checkups can improve cancer survival.  
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Top 10 Types of Cancer in Iowa Estimated for 2014
Human papillomavirus (HPV) is one of the most common sexually transmitted infections 
worldwide. There are more than 130 
HPV types that have been divided 
into low-risk and high-risk types 
based on their potential to cause 
cancer. HPV types 16 (HPV-16) and 
18 (HPV-18) account for most HPV-
related cancers. Other high-risk types 
include HPV-31, -33, -35, -39, -45, -51, 
-52, -56, -58, -59, -66, and -68. HPV-16 
infection has been shown to be the 
single most common high-risk type in 
most regions of the world, including 
the United States. HPVs are small 
double-stranded DNA viruses that 
infect epithelial cells. These cells cover 
the inside and outside surfaces of the 
body, including the head and neck 
and anogenital areas. Most people 
who become infected with HPV do 
not know they have it. Based on data 
involving cervical HPV infection, 
HPV is cleared from the body in 90% 
of infected individuals within two 
years and consequently does not 
cause health problems. The remaining 
10% have persistent infection and, 
within 30 years, about half of these  
develop cancer. 
HPV-related cancers are defi ned 
as cancers at specifi c anatomic sites 
with specifi c cellular types in which 
HPV DNA is frequently found. The 
association between HPV and cervical 
cancer is well established, and HPV 
infection is strongly implicated in 
cancers of the vagina, vulva, and 
penis. Over 90% of cervical cancers, 
more than 70% of vaginal cancers and 
over 60% of vulvar and penile cancers 
are likely caused by HPV infection 
(Table 1). In addition, over 90% of 
anal cancers and more than 70% of 
certain subsites of oropharyngeal 
cancers (including the base of the 
tongue, lingual and palatine tonsils, 
oropharynx, pharynx, and Waldeyer 
ring) are also probably caused by 
HPV infection (Table 1). 
HPV infection has been shown 
to be strongly related to sexual 
practices, including multiple 
sexual partners, oral sex, and 
anal intercourse. HPV causes an 
epidemiologically and clinically 
distinct form of oropharyngeal 
squamous cell carcinoma (OPSCC). 
HPV-positive OPSCCs have risk factors 
related to sexual behavior, whereas 
HPV-negative OPSCCs are strongly 
related to tobacco and alcohol use. 
Patients with HPV-positive OPSCCs 
have improved survival compared 
with HPV-negative OPSCC patients 
despite often presenting with more 
extensive cancers.  Also, patients 
with HPV-positive tumors who have 
been tobacco smokers appear to 
have a shortened survival relative 
to patients with just HPV-positive 
OPSCCs. The reasons for an improved 
outcome and response to therapy 
in patients with HPV-positive OPSCC 
are unclear.  
In Iowa between 2006 and 2011, 
there were a total of 2,107 cancers at 
HPV-related sites among men and 
women (811 and 1,296, respectively) 
(Table 1). They accounted for 2.2% 
of all microscopically-confi rmed, 
invasive cancers during this period. 
Cervical cancer alone represented 
46% of all HPV-related cancer among 
women and 29% of all HPV-related 
cancers; OPSCC accounted for 79% 
of HPV-related cancer among men 
(Table 1). Applying the percents 
probably caused by HPV infection 
(Table 1) to the total number of cases 
in Iowa between 2006 and 2011 
suggests that 1,576 of the 2,107 HPV-
related cancers (75%) were likely 
caused by HPV infection.  
 Human 
Papillomavirus (HPV)
Related Cancers
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Most people who 
become infected  with 
HPV do not  know
they have it .
HPV-related cancers are 
de ned as cancers at 
speci c anatomic sites 
with speci c cellular 
types in which HPV DNA 
is frequently found.
Over 90% of cervical 
cancers, more than 
70% of vaginal cancers 
and over 60% of vulvar 
and penile cancers 
are likely caused by 
HPV infection.
In 2009 in the United States, 
a total of 34,788 HPV-related 
cancers occurred among men and 
women. These cancers accounted 
for 3.3 percent of all invasive cancers 
diagnosed in 2009. Similar to the 
Iowa percent, cervical cancer alone 
represented 53% of all HPV-related 
cancer among United States’ women 
and 33% of all HPV-related cancers, 
whereas OPSCC accounted for 78% 
of HPV-related cancer among men. 
Looking back over 24 years 
(1988-2011) in Iowa, incidence rates 
under age 60 years at least doubled 
for anal cancer in both genders, vulvar 
cancer in women, and HPV-related 
OPSCC in men when comparing 1988-
93 rates with 2006-11 rates (Table 1). 
Similarly, HPV-related OPSCC also 
signifi cantly increased in males 60+ 
years old (Table 1). HPV-16 generally 
accounts for most of these cases. 
In Iowa the overall rise in OPSCC is 
largely explained by the increasing 
incidence at HPV-related cancer sites, 
whereas the incidence at non-HPV-
related cancer sites has remained 
stable (Figure 1). This increasing 
incidence of HPV-related OPSCC 
perhaps arises from increased oral 
sex and oral HPV exposure over past 
decades particularly among men 
under the age of 60. In contrast over 
this same period, cervical cancer 
incidence rates decreased for Iowa 
women, likely due to earlier treatment 
of precancerous disease as a result 
Table 1. 
Age-adjusted incidence rates* (number of cases) of HPV-related cancers‡ by sex, year and age of diagnoses, Iowa, 1988-2011
* Rates are per 100,000 and age-adjusted to the 2000 U.S. standard population.
‡ HPV-related cancers are de ned as cancers at speci c anatomic sites with speci c cellular types in which HPV DNA is frequently found.  Cases are invasive, microscopically-con rmed, 
 squamous cell carcinomas except for cervical cancer where adenocarcinomas are also included.
** Oropharynx subsites include base of tongue, tonsil, lingual and palatine tonsils, oropharynx, pharynx, and Waldeyer ring.
+ Rate is signi cantly di erent (p < 0.05) from corresponding 1988-93 rate. 
ŧ Data source: http://www.cdc.gov/cancer/hpv/statistics/cases.htm
^ Percent is for males and females combined.   
Male Female
Year and Age of 
Diagnoses
Anus Oropharynx** Penis Cervix Vagina Vulva Anus Oropharynx**
1988-93
<60 0.3 (15) 1.8 (103) 0.3 (19) 9.3 (593) 0.1 (7) 0.8 (48) 0.3 (16) 0.5 (32)
60+ 1.0 (14) 11.4 (164) 4.2 (57) 15.0 (289) 1.9 (39) 7.9 (159) 3.4 (66) 4.3 (82)
1994-99
<60 0.4 (26) 1.9 (123) 0.3 (22) 8.2 (560) 0.1 (7) 1.1 (71) 0.6 (42) 0.5 (36)
60+ 1.7 (24) 9.7 (139) 2.9 (38) 11.2+ (216) 1.8 (36) 8.6 (179) 2.8 (54) 3.2 (62)
2000-05
<60 0.3 (25) 3.2+ (246) 0.2 (15) 6.9+ (478) 0.1 (11) 1.2 (87) 0.9+ (70) 0.8 (63)
60+ 2.3 (34) 13.0 (191) 4.4 (62) 9.6+ (183) 1.7 (38) 6.6 (139) 3.3 (63) 3.0 (58)
2006-11
<60 0.6+ (50) 4.2+ (367) 0.2 (19) 6.4+ (448) 0.2 (13) 1.5+ (117) 1.3+ (105) 0.7 (59)
60+ 2.0 (32) 16.7+ (274) 4.5 (69) 7.8+ (154) 1.5 (31) 8.1 (176) 5.2 (105) 4.4 (88)
Probably 
caused by HPVŧ 91%^ 72%^ 63% 91% 75% 69% 91%^ 72%^
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of Pap testing. With current trends 
in Iowa and nationally, by 2020 the 
number of HPV-related OPSCCs is 
expected to surpass the number of 
cervical cancers, which have been 
the focus of HPV vaccination.    
Since 2006, HPV vaccines have 
been available in the United States. 
Currently two HPV vaccines are 
available to protect against HPV-
16 and HPV-18. Both vaccines are 
approved for the prevention of 
cervical cancers caused by these two 
HPV types. Since the vaccines prevent 
infection with HPV types that can 
also cause oropharyngeal cancers, 
it is highly likely the vaccines can 
prevent cancers occurring at these 
oral sites, as well, but studies have not 
yet been done to confi rm this. One 
of the vaccines also protects against 
HPV types 6 and 11, which cause 90% 
of genital warts, and has also been 
approved for prevention of vaginal, 
vulvar, and anal cancers. 
The Centers for Disease Control 
and Prevention (CDC) Advisory 
Committee on Immunization 
Practices (ACIP) recommends routine 
vaccination for girls ages 11 or 12 
with three doses of either of the two 
available HPV vaccines and routine 
vaccination of boys ages 11 or 12 with 
three doses of the vaccine that also 
covers HPV types 6 and 11. Vaccination 
is also recommended for females 
ages 13 through 26 and males ages 13 
through 21 who were not vaccinated 
previously. Males ages 22 through 26 
may also receive three doses of the 
vaccine. For men who have sex with 
men and for immunocompromised 
males, ACIP recommends routine 
vaccination with the vaccine that also 
covers HPV types 6 and 11 as stated 
above for all males, and vaccination 
through age 26 years for those who 
have not been vaccinated previously 
or who have not completed the 
3-dose series. 
In 2012, data collected in the 
CDC’s National Immunization Survey-
Teen showed that slightly more than 
half (54%) of adolescent girls ages 13 
through 17 nationwide had received 
one or more doses of HPV vaccine, 
0
2
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Cervix HPV-unrelated oropharynx sites HPV-related oropharynx sites
Figure 1. Incidence rates for selected HPV-related cancers, Iowa, 1988-2011
 (Rates are per 100,000 population and age-adjusted to the U.S. 2000 population.)
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With current trends in 
Iowa and nationally, 
by 2020 the number of 
HPV-related OPSCCs 
is expected to surpass 
the number of cervical 
cancers, which have 
been the focus of 
HPV vaccination. 
and one in three (33%) had received 
the recommended three doses, which 
is much lower than the coverage 
reported in neighboring countries 
and in many European nations. In 
Healthy People 2020 the United States 
target for HPV vaccination coverage 
among adolescent females is 80% for 
the recommended three doses. State-
level HPV vaccination coverage levels 
for one or more doses varied widely in 
2012 from 39% of adolescent girls in 
Florida to 74% in Rhode Island. Iowa’s 
percent was 58%. In 2012, this same 
survey showed that 21% of adolescent 
boys ages 13 through 17 nationwide 
and 19% in Iowa had received one or 
more doses of HPV vaccine. 
While HPV vaccination, containing 
HPV types 16 and 18, can protect 
against 70% of cervical cancers and 
signifi cant percents of HPV-related 
cancers at other sites, it does not 
protect against all cancer-causing 
types of HPV, which means cervical 
cancer can develop in women who 
have been vaccinated. Vaccinated 
and unvaccinated women should still 
be screened for cervical cancer via 
the Pap test. In Iowa and nationally 
in 2012, 78% of women 18+ years 
of age received a Pap test during 
the previous three years per CDC’s 
Behavioral Risk Factor Surveillance 
System (BRFSS) data. In Iowa, the 
highest percent was 93% among 
women in the 25-34 age group. The 
Iowa data also show that Pap testing 
varies substantially by education level 
with only 60% of those with less than 
high school education receiving Pap 
testing compared with 91% among 
college graduates (Figure 2). This may 
relate to lack of health insurance or 
a consistent source of medical care. 
The United States Preventive Services 
Task Force recommends screening 
for cervical cancer in women ages 21 
to 65 years with cytology (Pap smear) 
every 3 years or, for women ages 30 
to 65 years who want to lengthen the 
screening interval, screening with a 
combination of cytology and HPV 
testing every 5 years.
Since HPV vaccination 
does not protect against 
all cancer-causing types 
of HPV, vaccinated and 
unvaccinated women 
should still be screened 
for cervical cancer via 
the Pap test.
Figure 2. Percent of female population who have had a Pap test within the past  
 three years by education level, Iowa, 2012
 (Data source:  http://apps.nccd.cdc.gov/brfss/)
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AGRICULTURAL	HEALTH	STUDY
The Agricultural Health Study (AHS) 
is a long-term study of agricultural 
exposures (including pesticides) 
and chronic disease (especially 
cancer) among commercial or private 
pesticide applicators (and their 
spouses, if married) in Iowa and North 
Carolina. The study is funded through 
the National Cancer Institute and 
involves several federal agencies. 
We are in the 22nd year of the study. 
In the fi rst fi ve years, 89,658 
subjects (58,564 in Iowa and 31,094 
in North Carolina) were enrolled in 
the study. The total for Iowa included 
31,877 private applicators, 21,771 
spouses of private applicators, 
and 4,916 commercial applicators. 
Enrollment consisted of completing 
questionnaires about past exposures 
and health. The second phase of 
the study for private applicators 
and their spouses was completed 
at the end of 2003. It involved a 
telephone interview, a mailed dietary 
questionnaire, and collection of a 
cheek cell sample from all consenting 
cohort members. The telephone 
interview asked about pesticide use 
since enrollment, current farming and 
work practices, and health changes. 
The dietary health questionnaire 
asked about cooking practices and 
types of foods eaten, since cooking 
practices and diet may play a role in 
cancer and other health conditions. 
The cheek cells are being used to 
understand possible links between 
genetics, exposures, and disease. 
For commercial applicators, the 
second phase of the study was 
completed at the end of 2005. The 
study’s third phase began in 2005 and 
ended in 2010. It involved updating 
information about exposures and 
health. The fourth phase of the study 
began in the fall of 2011 and for the 
University of Iowa research team 
primarily involves collection of 
blood and urine samples from 
a select subgroup of AHS male 
participants and collection of 
buccal cells from AHS participants 
diagnosed with cancer.      
Since 1997, cohort members 
have been linked annually or 
biennially to mortality and cancer 
registry incidence databases in both 
states. In addition, mortality data 
on the cohort are being obtained 
from the National Death Index. 
More information about results from 
this study, the study background, 
frequently asked questions, other 
resources (internet & telephone) 
for agricultural health information, 
references for publications to 
date, and information for scientifi c 
collaborators can be found at the 
website, http://aghealth.nci.nih.gov/. 
The titles for over 190 publications 
from this study linked to PubMed 
are available at the website. The 
cancer-related references for 2013 
publications are provided in the 
last section of this report. 
AYA	HOPE	STUDY
The Adolescent and Young Adult 
(AYA) Health Outcomes and Patient 
Experience (HOPE) Study is another 
ongoing example of a cancer survivor 
study. This study is an initial step 
in addressing potential factors 
related to gaps in research, care and 
outcomes. From 7 SEER Registries 
across the United States, 525 patients 
(40 in Iowa), 15-39 years old at 
diagnosis between July 1, 2007 and 
October 31, 2008 have been enrolled 
with any of the following cancers:  
ovarian or testicular cancer, Hodgkin 
lymphoma, non-Hodgkin lymphoma, 
acute lymphoblastic leukemia, or 
selected types of sarcoma. Those who 
responded were representative of 
all AYA cancer survivors during this 
Research Projects 
During 2014
The State Health Registry of 
Iowa is participating in over 
60 active studies approved by 
the University of Iowa Human 
Subjects Oﬃ  ce during 2014. 
Brief descriptions of a few of 
these studies are provided.
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time period. 91% of the 525 have 
completed a subsequent survey  
8 to 17 months after the initial 
survey to obtain additional follow-up 
information regarding their cancer 
survivorship experience. During  
2013, additional publications that 
have reported findings from this 
study are provided in the last  
section of this report. 
IOWA	WOMEN’S	HEALTH	STUDY
This is a population-based cohort of 
41,837 Iowa women, aged 55-69, who 
were recruited in 1986 to determine 
whether diet, body fat distribution 
and other risk factors are related 
to cancer incidence. Exposure and 
lifestyle information was collected 
in a baseline mailed survey and 
subsequently in several follow-up 
mailed surveys. Mortality and cancer 
incidence have been ascertained 
since 1986 through annual linkage 
to the State Health Registry of 
Iowa databases and the National 
Death Index. In 2010 the study was 
refunded for its 25th through 29th 
years. This study’s data have also  
been pooled with data from other 
cohort studies and analyzed as 
international collaborative activities. 
Over time, this has led to over 250 
cancer-related publications, some  
of which occurred in 2013 and are 
listed in the references provided in 
the last section of this report. 
LUNG	CANCER	CARE	
OUTCOMES/SURVEILLANCE	
CONSORTIUM
This study involves a statistical 
coordinating center, the State Health 
Registry of Iowa, and five other 
primary data collection and research 
sites around the United States. 
Across these sites, we conducted 
population-based research in the 
areas of access to care and patterns 
of care for lung and colorectal cancer. 
We are evaluating the reasons for 
particular care decisions by patients 
and their physicians, including 
variation in disseminations of modern 
care protocols and practices in 
different geographic areas. We are 
also evaluating the effects of these 
decisions and practices on patient 
outcomes, including quality of life.  
In Iowa, this study was limited to lung 
cancer patients. Over 1,000 newly 
diagnosed lung cancer patients 
were enrolled between June 2003 
and March 2005. Thereafter, these 
patients provided consent for medical 
record abstraction and participated 
in follow-up interviews. Several 
publications have resulted from the 
findings and those that occurred  
in 2013 are provided in the last 
section of this report. 
NON-HODGKIN	LYMPHOMA	
(NHL)	CASE-CONTROL	STUDY
The State Health Registry of Iowa 
(SHRI) with other investigators at the 
Mayo Clinic participated in a 
collaborative, population-based case-
control study of NHL involving 
researchers at the National Cancer 
Institute and three other Surveillance, 
Epidemiology, and End Results (SEER) 
registries. The main objective of the 
study was to better characterize risk 
factors for NHL. In Iowa, 364 patients 
newly diagnosed with NHL between 
July 1, 1998 and June 30, 2000 were 
enrolled. A similar number of 
population controls participated. 
Blood samples were sought from 
study participants. The SHRI also 
coordinated the acquisition of 
pathology reports, slides and tissue 
blocks from all SEER centers. The 
slides were reviewed to determine 
the reliability of NHL pathologic 
classification. More recently, we 
collaborated with researchers to 
investigate whether genes with 
functional, common variant 
polymorphisms involved in  
immune function and regulation  
are associated with overall survival  
from NHL among these patients.  
To achieve this aim, medical record 
reviews were performed to obtain 
more detailed information on the 
treatment received for NHL. This 
study’s data have also been pooled 
with data from other NHL case-
control studies and analyzed as  
part of the InterLymph Consortium,  
a group of international investigators 
who discuss and undertake research 
activities with these data. All of  
these research activities resulted in 
several publications during 2013.  
The references for these are provided 
in the last section of this report. 
SECOND	CANCER	STUDIES	
INCLUDING	THE	WECARE	STUDY
Over the past three decades, the 
State Health Registry of Iowa has 
participated in several second cancer 
studies. These have consisted of 
cohorts with a first cancer of the 
cervix, ovary, testis, uterus, female 
breast, non-Hodgkin lymphoma, or 
Hodgkin disease. They have been 
conducted primarily in collaboration 
with Radiation Epidemiology Branch 
at the National Cancer Institute and 
other registries in North America 
and Europe. Generally these studies 
evaluate the treatment received for 
the first cancer and the risk it places 
on the patient for development of a 
second cancer. They typically involve 
medical record review and pathology 
material retrieval. Currently, we are 
evaluating esophagus, pancreas, and 
stomach as second cancer sites in 
several of these cohorts, mentioned 
above, with a first cancer.   
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The	WECARE	
(Women’s Environmental Cancer and 
Radiation Epidemiology) Study is an 
example of a second cancer study. 
This study is designed to examine 
gene carrier status, demographic 
and lifestyle factors as well as 
environmental and treatment factors 
reported to be associated with an 
initial breast cancer as they relate to 
the development of a second breast 
cancer in the opposite breast. 
Eligible cases were diagnosed 
with a fi rst breast cancer between 
1985 and 2009 that did not spread 
beyond the regional lymph nodes 
at diagnosis and a second primary 
contralateral breast cancer diagnosed 
at least one year after the fi rst breast 
cancer diagnosis. Eligible controls 
were women with unilateral breast 
cancer who were individually 
matched to cases on year of birth, 
year of diagnosis, registry region, 
and race. The controls must have 
survived without any subsequent 
diagnosis of cancer and with an 
intact contralateral breast during 
the interval that elapsed between 
their matched case’s fi rst and 
second breast cancer diagnoses. 
Data collection not only involved 
medical record review, but also 
participant interviews and biosample 
collection, either cheek cells or 
blood. The WECARE staff  is collecting 
mammographic fi lm data for its 
research subjects in 2014 to evaluate 
breast density as another risk factor 
for a subsequent diagnosis of invasive 
breast cancer in the contralateral 
breast. A listing of publications 
during 2013 from second cancer 
studies, including the WECARE Study, 
is provided in the last section of 
this report.
SEER-MEDICARE
In the early 1990s, the cancer 
incidence and survival data from 
the State Health Registry of Iowa 
was combined with other SEER 
Registry data and linked to Medicare 
data. This linked data set has been 
updated on several occasions since 
and has become an important data 
resource for cancer research involving 
epidemiologic and health services 
research related to the diagnosis 
and treatment procedures, costs, 
and survival of cancer patients. Over 
the years many publications have 
resulted from this linked data set 
including several during 2013, which 
are listed at http://healthservices.
cancer.gov/seermedicare/overview/
publications.html. 
STUDIES	INVOLVING	TISSUE
Today, researchers are increasingly 
looking to obtain tissue to study 
molecular characteristics of cancers. 
Several studies that involve the State 
Health Registry of Iowa have included 
tissue. During 2013, several articles 
involving tissue from Iowans were 
published, the references for which 
are provided in the last section of 
this report.     
TRANSPLANT	CANCER	MATCH	
STUDY
Solid organ transplantation 
provides life-saving treatment 
for end-stage organ disease but 
is associated with substantially 
elevated cancer risk, largely due 
to the need to maintain long-term 
immunosuppression. Important 
questions remain concerning the 
role of immunosuppression and 
other factors in causing cancer in this 
setting. Staff  at two federal agencies, 
the National Cancer Institute (NCI) 
and the Health Resources and 
Services Administration (HRSA), 
are creating a database through 
linkage of information during 1987-
2009 on 207,889 U.S. transplant 
recipients, wait list candidates 
(119,287 in addition to those who 
were subsequently transplanted), 
and donors (60,297 deceased 
donors, 49,054 living donors) with 
information on cancer from 15 U.S. 
cancer registries, including the State 
Health Registry of Iowa. These data 
are being used to conduct research 
concerning the spectrum of cancer 
risk in transplant recipients. The 
data will also be used by HRSA in its 
public health role overseeing the 
U.S. solid organ transplant network 
to maintain and improve safety of 
organ transplantation, and will allow 
NCI to better characterize the burden 
of cancer in this population and 
discover additional factors associated 
with cancer among this population.
COOPERATIVE	AGREEMENTS	
AND	OTHER	REGISTRIES
In the Midwest, the SHRI maintains 
cooperative agreements with several 
states, hospital cancer registries, and 
other agencies/entities. Some of the 
latter include:
 Iowa Department of Public Health
 Iowa Cancer Consortium 
 The University of Iowa
• Center for Health E ects of Environmental  
 Contamination
• Center for Health Policy and Research
• Center for Public Health Statistics
• Environmental Health Sciences 
 Research Center
• Health E ectiveness Research Center
• Holden Comprehensive Cancer Center
• Iowa Center for Agricultural Safety and Health
• Iowa Center for Education and Research on  
 Therapeutics (Iowa CERT)
• Injury Prevention Research Center
• Nutrition Center
• Preventive Intervention Center 
• Reproductive Molecular Epidemiology  
 Research & Education Program
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